Search clinical trials for: Flucytosine (5-FC, Ancotil)

Total 23 results

Transgene

Terminated

Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.

Colorectal Neoplasm | Digestive System Neoplasm

France, Spain, Belgium
Assistance Publique - Hôpitaux de Paris
Transgene

Unknown

Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients (ONCOVIRAC)

Glioblastoma | Brain Cancer

France
Tocagen Inc.

Completed

Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

Glioblastoma Multiforme | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Tocagen Inc.

Completed

A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma

Glioblastoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Tocagen Inc.

Terminated

A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511

Astrocytoma | Glioblastoma Multiforme | Gliomas, Malignant

United States
Tocagen Inc.

Completed

Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor

Glioblastoma Multiforme | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Tocagen Inc.

Withdrawn

A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

Bladder Cancer
Ashish Shah
National Cancer Institute (NCI); Denovo Biopharma LLC

Not yet recruiting

A Biomarker-Guided Phase 2 Study of DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) Extended-Release Tablets

High Grade Glioma | Anaplastic Astrocytoma

United States
Transgene

Terminated

Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

France, United Kingdom
Anaeropharma Science, Inc.

Suspended

Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

Neoplasms | Cancer | Tumors

United States
Transgene

Completed

Trial of TG4023 Combined With Flucytosine in Liver Tumors

Hepatocellular Carcinoma

France
Themis Bioscience GmbH
Assign Data Management and Biostatistics GmbH; Optimapharm

Withdrawn

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

Gastrointestinal Cancer

Germany
Tocagen Inc.

Withdrawn

A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care (Toca7)

Newly Diagnosed High Grade Glioma (HGG)
Tocagen Inc.

Terminated

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Melanoma | Sarcoma | Lymphoma | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | IDH1 Mutated Solid Tumors | IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)

United States
City of Hope Medical Center

Completed

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

Recurrent High Grade Glioma | Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Recurrent Adult Brain Tumor | Recurrent Grade III Glioma | Adult Brain Tumor | Recurrent Grade IV Glioma | Adult Anaplastic...

United States
Tocagen Inc.

Terminated

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (Toca5)

Glioblastoma Multiforme | Anaplastic Astrocytoma

United States, Korea, Republic of, Canada, Israel
NRG Oncology
National Cancer Institute (NCI)

Withdrawn

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

Glioblastoma | Anaplastic Astrocytoma | Oligodendroglioma | Supratentorial Glioblastoma
Tasly Tianjin Biopharmaceutical Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

Anaplastic Oligoastrocytoma | Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS

Cryptococcal Meningitis

South Africa
National Cancer Institute (NCI)

Recruiting

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

Lynch Syndrome

United States, Puerto Rico
Klinički Bolnički Centar Zagreb
University of Zagreb

Recruiting

Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD

Ocular Hypertension | Primary Open-angle Glaucoma

Croatia
OncoSil Medical Limited

Recruiting

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma (TRIPP-FFX)

Locally Advanced Pancreatic Cancer

Spain, Belgium, United Kingdom, Italy, Australia

Search clinical trials for: Flucytosine (5-FC, Ancotil)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations